Among the problems faced by people with Huntington’s disease (HD), a common one is weight loss. Many individuals with the disease lose weight over time, even when they are trying to eat enough. This ...

Today, Roche announced in a community letter difficult news for the Huntington’s disease (HD) community, discontinuing two separate clinical programmes after new data emerged from ongoing studies. The ...

No, not a puppy or a kitten or even a pet turtle, but a PET tracer to visualize huntingtin (HTT) protein in living subjects. PET stands for Positron Emission Tomography, an imaging technique that can ...

uniQure shared in a press release on June 17, 2026 that the Food and Drug Administration (FDA) has agreed the 3-year data from their Phase I/II study can serve as the basis for a Biologics License ...

Huntington’s disease (HD) involves the loss of cells in the striatum, an area of the brain that plays important roles in movement, cognition, and behaviour. For decades, researchers have been ...

A recent collaboration between researchers at the University of Leiden and the Huntington Expertise Center Topaz Overduin in the Netherlands has focused on an important yet often overlooked part of ...

The Total Functional Capacity scale, or TFC, was developed in 1979 by researchers Dr. Stanley Fahn and the late Dr. Ira Shoulson, founder of the Huntington Study Group. They wanted to describe the ...

Anew study using precise gene editing in a Huntington’s disease (HD) mouse model provides evidence that a small fragment of the huntingtin (HTT) protein, called HTT1a, is a central driver of HD. By ...

A new collaboration between researchers at Indiana University Southeast and Bellarmine University in Kentucky, both in the USA, aimed to investigate what happens when a physical therapist and a music ...

Greetings from Day 2 of the CHDI HD Therapeutics Conference! HDBuzz continues to provide summaries of the exciting talks from HD scientists gathered in Palm Springs from around the world. This day’s ...

For individuals in the HD “grey zone” between 36-39 repeats, an understanding of when symptoms may arise and what kind of symptoms is critical. A new study sheds light on different sequence patterns ...

A new Huntington’s disease (HD) clinical trial has reached an important milestone: the first participants have now been dosed in POINT-HD, a Phase 1 study testing a new, selective huntingtin-lowering ...